1. Introduction {#S1}
===============

Phase I clinical trials mark the first experimentation of a new drug in a human population. For cytotoxic anti-cancer drugs, the aim of a phase I trial is to gradually adapt the dose level of the drug given to patients in order to identify the Maximum Tolerated Dose (MTD), defined as the largest dose that leads to unacceptable toxicity in a target proportion, *θ*, of patients ([@R2]). The rationale for targeting such a dose is based on the assumption that higher doses will be more effective, yet more toxic ([@R12]), and that toxicity is tolerable for optimal anti-tumour activity ([@R3]). Toxicities are graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) ([@R16]), and are usually reduced to a single binary outcome, which denotes whether a Dose-Limiting Toxicity (DLT) has occurred or not ([@R15]). Therefore, for a pre-specified Target Toxicity Level (TTL) of *θ*, the definition of the MTD can be expressed mathematically as $$\mathbb{P}\left( {\text{DLT}{\ \left| \ {dose} \right.} = \text{MTD}} \right) = \theta.$$

Since an unknown portion of the dose range will be too toxic for patients, a *dose-escalation* study is conducted, rather than randomly allocating patients over discrete dose levels and then estimating the MTD ([@R11]). Furthermore, sample sizes in phase I oncology trials are often very small, which means that multiple testing procedures that incorporate dose-toxicity orders are not particularly useful ([@R18]). To avoid these issues, several Bayesian adaptive methods, which sequentially recommend dose adaptations and borrow information from lower dose levels and prior beliefs, have been proposed for conducting dose-escalation studies and estimating the MTD ([@R17]; [@R3]; [@R9]). The escalation with overdose control (EWOC) approach ([@R3]) is a Bayesian adaptive design that reduces the risk of overdosing patients by choosing doses with a posterior probability of being above the true MTD equal to some value known as a *feasibility bound*. The feasibility bound, denoted as *α*, controls how conservative dose-escalation during the trial is and was originally suggested to be fixed throughout the trial. Several publications ([@R1]; [@R6]; [@R20]) describe trials where *α* increases during the trial so that eventually dose-selection is based on the posterior median of the MTD distribution; at this point the posterior probability of dosing above the true MTD is identical to dosing below the true MTD. Whilst such a design provides improved operating characteristics relative to the EWOC approach with a fixed feasibility bound ([@R10]), there is no guarantee of *coherent* dose-escalation ([@R7]; [@R20]; [@R8]) that is, dose escalation may be recommended despite having observed a DLT in the previous patient.

This paper formalises a proof that incoherent dose-escalation can occur when the feasibility bound is increased after observing toxicity in a dose-escalation trial using the EWOC approach. Along with a new theoretical result, several simulation studies are conducted for a trial of 5-fluorouracil (5-FU) ([@R3]) using the EWOC approach to see which situations are more likely to yield incoherent dose escalations when the feasibility bound is increased during a trial. Recommendations for practical implementation of the EWOC approach with a varying feasibility bound are provided in the Discussion.

2. Escalation with overdose control {#S2}
===================================

2.1. Overview {#S3}
-------------

Let *Y~i~* be a binary random variable such that *Y~i~* = 1 if patient *i* experiences a DLT and *Y~i~* = 0 otherwise. For a dose range of interest, bounded below by *x*~min~ and above by *x*~max~, denote the probability of DLT for patient *i* at dose level *x* ∈ \[*x*~min~, *x*~max~\] by *π* (*x*; ***β***), where ***β*** is a parameter vector. Several structural forms for *π* (*x*; ***β***) have been proposed ([@R8]), but we shall only consider the two-parameter logistic model proposed in the original EWOC paper ([@R3]), i.e. $$\mathbb{P}\left( {Y_{i} = 1\left| \ {\text{dose} = x} \right.} \right) = \pi\left( {x;\beta_{0},\beta_{1}} \right) = \frac{\text{exp}\left( {\beta_{0} + \beta_{1}x} \right)}{1 + \text{exp}\left( {\beta_{0} + \beta_{1}x} \right)},$$ where *β*~0~ and *β*~1~ are parameters to be estimated and *β*~1~ \> 0 to ensure the assumption of monotonicity is satisfied (i.e. probability of DLT is non-decreasing with dose). Rearranging [Eq. 2](#FD2){ref-type="disp-formula"} using [Eq. 1](#FD1){ref-type="disp-formula"}, the MTD, denoted as *γ*, can be written as $$\gamma = \frac{\text{logit}\left( \theta \right) - \beta_{0}}{\beta_{1}}.$$ Under the original EWOC approach, *π* (*x*; *β*~0~, *β*~1~) is expressed in terms of two clinically relevant parameters: the MTD *γ* ([Eq. 3](#FD3){ref-type="disp-formula"}); and the probability of DLT at the lowest dose level to be used in the trial, denoted as *ρ*~0~, where $$\rho_{0} = \pi\left( {x_{\text{min}};\beta_{0},\beta_{1}} \right) = \frac{\text{exp}\left( {\beta_{0} + \beta_{1}x_{\text{min}}} \right)}{1 + \text{exp}\left( {\beta_{0} + \beta_{1}x_{\text{min}}} \right)}.$$ We therefore write *π* (*x*; *β*~0~, *β*~1~) as *π* (*x*; *γ*, *ρ*~0~) and use a Bayesian updating procedure by placing prior distributions upon *γ* and *ρ*~0~ ([@R14]); [@R3] suggest a Uniform prior distribution for *γ* over the interval \[*x*~min~, *x*~max~\], and a Uniform prior distribution for *ρ*~0~ over the interval \[0, *θ*\], since *ρ*~0~ \> *θ* implies that the MTD *γ* is lower than *x*~min~.

We condition all subsequent calculations on the event that *Y*~1~ = 0 (i.e. the first patient did not experience a DLT; if *Y*~1~ = 1, then it is recommended that the trial is suspended for safety concerns and the experimental dose range re-evaluated or the trial terminated ([@R3]; [@R21]; [@R20])). Given the set of trial data for *n* patients $\mathcal{D}$~*n*~ = {(*x~i~*, *y~i~*) : *i* = 1,..., *n*}, where patient *i* received dose *x~i~* ∈ \[*x*~min~, *x*~max~\] and had outcome *y~i~* ∈ {0, 1}, the joint likelihood function for *γ* and *ρ*~0~ is $$L\left( \gamma,\rho_{0} \middle| \mathcal{D}_{n} \right) = {\prod\limits_{i = 1}^{n}{\pi\left( {x_{i};\gamma,\rho_{0}} \right)^{y_{i}}\left\lbrack {1 - \pi\left( {x_{i};\gamma,\rho_{0}} \right)} \right\rbrack^{1 - y_{i}}}}.$$ For some joint prior *f* (*γ*, *ρ*~0~) on parameters *γ* and *ρ*~0~ (we assume the aforementioned independent Uniform priors; other frameworks are available ([@R21])), we obtain the joint posterior distribution *g* (*γ*, *ρ*~0~ \| $\mathcal{D}$*~n~*) via Bayes' Theorem and hence the marginal posterior cumulative distribution function (CDF) for the MTD *γ* is $$H_{n}\left( \gamma^{\prime} \right) = \mathbb{P}\left( \gamma \leq \gamma^{\prime} \middle| \mathcal{D}_{n} \right) = {\int_{x_{\text{min}}}^{\gamma^{\prime}}{\int_{0}^{\theta}{g\left( \gamma,\rho_{0} \middle| \mathcal{D}_{n} \right)d\rho_{0}}}}d\gamma.$$ Dose allocation for future patients is determined by selecting the 100*α*th percentile from the posterior MTD distribution, i.e. the dose for the (*n* + 1)th patient, denoted *x*~*n*+1~, is $x_{n + 1} = H_{n}^{- 1}\left( \alpha \right).$ The constant *α* is defined as the *feasibility bound* and governs the degree of conservatism present in the trial. The feasibility bound can be interpreted via a decision-theoretic loss function, which describes the relative preference of underdosing a patient compared to overdosing a patient. For some dose level *x* and MTD *γ*, the loss function for feasibility bound *α* is $$\text{Loss}\left( {x,\gamma} \right) = \begin{cases}
{\alpha\left( {\gamma - x} \right)} & {\text{if}\ x\ \text{is}\ \text{an}\ \text{underdose},\ \text{i}.\text{e}.\ x \leq \gamma} \\
{\left( {1 - \alpha} \right)\left( {x - \gamma} \right)} & {\text{if}\mspace{7mu} x\ \text{is}\ \text{an}\ \text{overdose},\ \text{i}.\text{e}.x \geq \gamma.} \\
\end{cases}$$ Equivalently, for any *δ* \> 0, the loss incurred by overdosing a patient (with respect to the MTD *γ*) by *δ* units is $\frac{1 - \alpha}{\alpha}$ times greater than underdosing a patient by *δ* units ([@R3]; [@R1]). For *α* \< 0.50, the loss function in [Eq. 6](#FD7){ref-type="disp-formula"} places a higher penalty on overdosing, whereas *α* = 0.50 penalises overdosing and underdosing equally severely. We only consider the loss function given in [Eq. 6](#FD7){ref-type="disp-formula"} for dose recommendations, though alternative myopic loss functions, or even balanced loss functions (if we wished to estimate the dose-toxicity relationship in full as well as identify the MTD) could be considered ([@R13]).

2.2. Increasing the feasibility bound mid-trial {#S4}
-----------------------------------------------

The idea of increasing the feasibility bound during the trial has been discussed ([@R1], [@R2]) and used in practice ([@R1]; [@R6]; [@R20]). At the beginning of the trial *α* is set to some minimal level strictly less than 0.50, so that the first patients that enter the trial are treated at safe doses with a high probability. As data are accrued, one can afford to be less conservative about dose-escalation, since the precision of the MTD distribution is increasing. To facilitate this, *α* can be gradually increased towards 0.50, at which point patients will be treated at the posterior median estimate of the MTD distribution. With respect to the loss function in [Eq. 6](#FD7){ref-type="disp-formula"}, when *α* tends towards 0.50, the implication is that investigators become less concerned with underdosing relative to overdosing; when *α* = 0.50, the penalty for underdosing is identical to that of overdosing.

3. Coherence violations {#S5}
=======================

For fixed *α* throughout the trial, the EWOC approach is coherent in escalation and de-escalation ([@R20]). We show that for increases in *α* after observing DLT outcomes, incoherent dose-escalation may occur.

3.1. Theoretical work {#S6}
---------------------

Let *H~n~*(*γ*) be the posterior CDF of the MTD parameter *γ*, as defined in [Eq. 5](#FD6){ref-type="disp-formula"}. Define *α~n~* to be the value of *α* used to choose the dose *x~n~* ∈ \[*x*~min~, *x*~max~\] for patient *n*. Therefore $\left. H_{n - 1}\left( x_{n} \right) = \alpha_{n}\Leftrightarrow H_{n - 1}^{- 1}\left( \alpha_{n} \right) = x_{n}. \right.$ First, we recall what it means to be *coherent in dose-escalation*.

**Definition 1** (*Coherent in dose-escalation*) Let *H~n~*(*x*) denote the posterior CDF of the MTD parameter *γ* given trial data for the first *n* ≥ 2 patients. Assume *H~n~*(*x*) is well-defined and infinitely differentiable on (*x*~min~, *x*~max~). A dose-escalation design is said to be coherent in dose-escalation if and only if *x*~*n*+1~ ≤ *x~n~* whenever *y~n~* = 1.

To show coherence in dose-escalation for the EWOC approach with fixed *α*, it is sufficient to show *H~n~*(*x*) ≥ *H*~*n*−1~(*x*) for all *x* ∈ \[*x*~min~, *x*~max~\] and *n* ≥ 2.

**Theorem 2** (Coherence of EWOC with fixed *α*) *For α~n~* = *α* ∈ \[0, 1\] *for all n, when* $\left. y_{n} = 1,H_{n}\left( t \right) \geq H_{n - 1}\left( t \right)for\ all\ t \in \left\lbrack {x_{\text{min}},x_{\text{max}}} \right\rbrack\Leftrightarrow H_{n}^{- 1}\left( \alpha \right) \leq H_{n - 1}^{- 1}\left( \alpha \right)\Leftrightarrow x_{n + 1} \leq x_{n}. \right.$

*Proof* See appendix of [@R20] for proof.

We build upon this result to prove the possibility of incoherent dose-escalation when the feasibility bound is increased following a patient experiencing a DLT.

**Theorem 3** (Non-guarantee of coherence in escalation) *Assume that $H_{n}^{- 1}\left( 1 \right) > x_{n},$ where *H~n~*(*x*) is as defined by [Eq. 5](#FD6){ref-type="disp-formula"} and Definition* [1](#P12){ref-type="other"}. *Then there exists some α*\* \> *α~n~* *such that* $H_{n}^{- 1}\left( \alpha^{*} \right) > H_{n - 1}^{- 1}\left( \alpha_{n} \right)$ *when* *y~n~* = 1.

*Proof* Both *H~n~*(*x*) and *H~n−1~*(*x*) are continuous and non-decreasing in *x*. By applying Theorem [2](#P14){ref-type="other"} and the Intermediate Value Theorem, and given $H_{n}^{- 1}\left( 1 \right) > x_{n},$ (i.e. *x~n~* \< inf {*x* : *H~n~*(*x*) = 1}), there exists some *α*′ ≥ *α~n~* that must give $H_{n}^{- 1}\left( \alpha^{\prime} \right) = x_{n} = H_{n - 1}^{- 1}\left( \alpha_{n} \right).$ Furthermore, since *H~n~* is continuous and non-decreasing, $H_{n}^{- 1}\left( \alpha^{*} \right) > H_{n - 1}^{- 1}\left( \alpha^{\prime} \right)$ for *α*\* \> *α*′, with equality existing if and only if lim~*t*\ →*x~n~*~ *H*′ (*t*) = ∞, which violates the assumption that *H~n~*(*x*) is infinitely differentiable on the interval (*x*~min~, *x*~max~). Therefore, given $H_{n}^{- 1}\left( 1 \right) > x_{n},$ there exists an *α*\* satisfying *α~n~* ≤ *α*′ \< *α*\* ≤ 1 such that $H_{n}^{- 1}(\alpha*) > H_{n - 1}^{- 1}(\alpha_{n})$ when *y~n~* = 1.

Theorem [3](#P17){ref-type="other"} considers the case where $H_{n}^{- 1}\left( 1 \right) > x_{n},$ otherwise we are in the case where $H_{n}^{- 1}\left( 1 \right) < H_{n - 1}^{- 1}\left( \alpha_{n} \right) = x_{n},$ and incoherent escalation is impossible for all *α* ≥ *α~n~*. Whilst this is entirely plausible, Theorem [3](#P17){ref-type="other"} shows that there can still exist instances whereby incoherent dose-escalation may occur. We explore this with a practical example in [Sect. 3.2](#S7){ref-type="sec"}.

3.2. Practical example {#S7}
----------------------

Consider the trial described by [@R3] that used the EWOC approach to find the MTD of 5-fluorouracil (5-FU) when given in combination with 20 mg/m^2^ leucovorin and 0.5 mg/m^2^ topotecan to patients with malignant solid tumours. In this trial, *x*~min~ = 140, *x*~max~ = 425 and $\theta = \frac{1}{3}.$ The dose-toxicity model in [Eq. 2](#FD2){ref-type="disp-formula"} was used with *γ* \~ *U* \[*x*~min~, *x*~max~\] and *ρ*~0~ \~ *U* \[0, *θ*\] *a priori*, and *γ* and *ρ*~0~ independent. For this trial, *α* was fixed at 0.25 throughout. We simulate a trial of 40 patients, assuming the true MTD value (*γ*^True^) is 300 mg/m^2^ and the true probability of DLT at $x_{\text{min}}\left( \rho_{0}^{\text{True}} \right)$ is 0.08. We observe the minimum size difference between *α*~*n*+1~ and 0.25 required to generate an incoherent dose-escalation, had an increasing feasibility bound approach been implemented after patient *n*, via the following procedure: Let *n* = 1 and *α* = 0.25. Dose patient 1 at *x*~1~ = *x*~min~ and let *Y*~1~ = 0 (otherwise trial does not proceed).For 2 ≤ *n* ≤ 40: (a)Given trial data $\mathcal{D}$~*n*−1~ = {*x*~1~, *y*~1~,..., *x*~*n*−1~, *y*~*n*−1~}, dose patient *n* at the dose recommended as per the standard EWOC approach $\left( {x_{n} = H_{n - 1}^{- 1}\left( \alpha \right)} \right)$ and set *y~n~* = 1.(b)Obtain the posterior CDF for *γ*, *H~n~*(*γ*).(c)Using *H~n~*(*γ*), find the minimum value of *α* ∈ $\mathcal{A}$ = {0.26,..., 0.50} that gives an incoherent dose-escalation for patient *n* + 1, i.e. $$\alpha_{n + 1}^{\text{min}} = \text{min}\ \left\{ {\alpha \in \mathcal{A}:H_{n}^{- 1}\left( \alpha \right) > x_{n}} \right\}.$$(d)Record $\alpha_{n + 1}^{\text{min}}.$ and re-generate *Y~n~* from the Bernoulli distribution with probability $\pi\left( {x_{n};\gamma^{\text{True}},\rho_{0}^{\text{True}}} \right).$(e)Repeat steps a)-d) with updated sample size *n* ← *n* + 1 and updated filtration $\mathcal{D}$~*n*~ ← {$\mathcal{D}$~*n*−1~, *x~n~*, *Y~n~* }.

[Table 1](#T1){ref-type="table"} shows one simulated trial, with patient number, observed DLT outcome, dose given and minimum feasibility bound required to guarantee incoherent dose-escalation, should the DLT outcome of the previous patient actually be equal to 1. As more patients are recruited into the trial, the value of $\alpha_{n + 1}^{\text{min}}$ tends to decrease. This is because as more data are accrued, the variance around *H~n~*(*γ*) decreases and new data provide smaller shifts in the position of *H*~*n*+1~(*γ*) relative to *H~n~*(*γ*). The same phenomenon will occur when strong prior distributions are placed on the model parameters (see [Sect. 3.3](#S8){ref-type="sec"}) and therefore $\alpha_{n + 1}^{\text{min}}$ for small *n* is more likely to be much lower than the figures presented in [Table 1](#T1){ref-type="table"}. Although this is only one simulated trial, increases in the feasibility bound by 0.04 or 0.05, which are increment sizes that have been used in actual trials ([@R20]), generate incoherent escalations in patients recruited into the trial later on. We now conduct several simulation studies to explore how the number of dose levels available and the strength of prior probability distributions affect the distribution of $\alpha_{n + 1}^{\text{min}}.$

3.3. Simulation studies {#S8}
-----------------------

To investigate the required increase in the feasibility bound to yield incoherent dose escalations, simulation studies for six different EWOC trial setups were conducted ([Table 2](#T2){ref-type="table"}). Scenario 1 is identical to the setup specified in [Sect. 3.2](#S7){ref-type="sec"}, and scenarios 2, 3 and 4 are the same as scenario 1, but with discrete dose levels at different intervals. Scenarios 5 and 6 are the same as scenario 1, except the priors are specified differently; scenario 5 has skewed priors that place more weight on the MTD being at the lower end of the dose range, whereas scenario 6 is a strong prior that assumes the MTD is in the middle of the dose range. Both of these scenarios depend on Beta prior distributions that assume an effective sample size of 10 patients (calculated by summing the parameters of the Beta distribution). For each scenario, 100 trials were simulated using the same procedure specified in [Sect. 3.2](#S7){ref-type="sec"}. [Figure 1](#F1){ref-type="fig"} shows the mean and 95% credible intervals for the distribution of $\alpha_{n + 1}^{\text{min}}$ as the trial progresses for all six scenarios. Across scenarios 1, 2, 3 and 4, the mean trajectory of $\alpha_{n + 1}^{\text{min}}$ over the trial differs depending on the number of dose levels; on average, larger increases in the feasibility bound are required to generate incoherent dose escalations as the number of available dose levels decreases. The 95% credible intervals are wider when fewer dose levels are available; this is because there are fewer instances when incoherent dose escalations arise when the feasibility bound can reach at most 0.50. Scenarios 2, 3 and 4, where 20, 16 and six evenly-spaced discrete dose levels are used respectively, show the mean of $\alpha_{n + 1}^{\text{min}}$ to decrease to around 0.40 for most of the trial (scenario 4 95% CI (0.30, 0.49)), whereas scenario 1 shows a gradual mean decrease to 0.32 at patient 40 (95% CI (0.29, 0.36)). This means that upon observing a DLT after patient *n* in a trial, increases in the feasibility bound by 0.04 or 0.05 could be enough to provide an incoherent dose escalation for patient *n* + 1; in scenario 4 this occurs before patient 10, meaning that patients recruited at the start of the trial could be recommended an increase of at least 57 mg/m^2^ even after observing a DLT in the previous patient. Under scenarios 5 and 6, which used strong skewed and strong symmetric priors respectively, small increases in the feasibility bound are required to generate an incoherent dose-escalation even early on in a trial; at patient 10, the mean of $\alpha_{n + 1}^{\text{min}}$ is 0.30 (95% CI (0.28, 0.33)). This is because the change in the posterior cumulative distribution function of the MTD after incorporating new data is much smaller when stronger priors are used.

4. Discussion {#S9}
=============

This paper formally outlines how incoherent dose-escalation can occur in phase I oncology trials when increasing the feasibility bound after observing toxicity under the EWOC approach. The example presented in [Sect. 3.2](#S7){ref-type="sec"} shows that even small increases in the feasibility bound can be enough to cause incoherent dose-escalation. The simulation studies presented in [Sect. 3.3](#S8){ref-type="sec"} also indicate that this is the case for different dose ranges and prior specifications. Interestingly, small changes in the feasibility bound could lead to incoherent dose-escalations being recommended early on in the trial, particularly if strong priors are used or few dose levels are considered. The key message is that incoherence can occur and that a design's operating characteristics and chance of permitting incoherent escalation should be fully determined before an actual trial is conducted. Arbitrary increases in the feasibility bound as per the trials referenced in [Sect. 2.2](#S4){ref-type="sec"} are best avoided by escalating the feasibility bound only in the absence of DLTs, thus guaranteeing coherent dose-escalation and de-escalation. However, this should not exclude investigators from assessing how a trial design may perform for increases in the feasibility bound; large changes in *α~n~* increase the risk of patients experiencing severe toxicity. The approach for changing the feasibility bound should ideally be specified before the trial begins; ad hoc changes to the planned increases in the feasibility bound during the trial could result in a poor understanding of the design's future behaviour, and on a practical level, require changes in the trial protocol to be made. Equally, one would be choosing the feasibility bound based on the dose that they wanted to use, rather than considering where it is on the MTD distribution. Before the trial, one may run simulation studies similar to those in [Sect. 3.3](#S8){ref-type="sec"} in order to determine how large increases in the feasibility bound might affect the dose-escalation behaviour of a trial design. This can be undertaken for trials with continuous or discrete doses, strong or weak priors, and can help clinicians determine when in the trial to reduce how conservative they wish to be in dose escalation. The results of this work show that in some scenarios, the feasibility bound need not increase by a lot before an incoherent escalation is observed, which suggests it is safer to increase the feasibility bound only in the absence of toxicity, whilst still converging to the MTD ([@R22]). [@R4] have previously considered the frequency of coherence violations under the EWOC design with increasing feasibility bounds, yet focused on the ability of the model to recommend the correct MTD and other operating characteristics. Whilst designs with superior operating characteristics with respect to patient safety and accurate MTD estimation are to be encouraged in practice, ensuring that incoherent dose escalation is not possible should also be a priority to prevent unsafe dose escalations being recommended and reduce the risk of having to make unexpected changes to the design mid-trial. Even for approaches that converge to the true MTD, the fluctuation of the dose level around and above the true MTD means that incoherent escalations may occur at both low and high dose levels. Therefore, there is a risk of escalating the dose to a severely toxic level when the feasibility bound is increased after observing a DLT, and this can be from either a tolerable or intolerable dose.

It should be made explicit that this work is not a refutation of the EWOC approach, or indeed a call to prevent changing the feasibility bound mid-trial. Model-based adaptive designs for phase I trials, many of which have been shown to supersede the traditional 3 + 3 approach ([@R5]; [@R19]) have been carefully developed over the last 25 years ([@R15]), and much work has been done to increase their prevalence in clinical practice. The EWOC approach is a welcome addition to the family of model-based designs and increasing the feasibility bound during a trial is a sensible idea in order to escalate towards the true MTD faster than usual whilst mitigating the risk of overdosing patients. Whatever the choice of dose-escalation design, operating characteristics should be well-assessed and compared to other available approaches, and should be done so on a trial-by-trial basis.
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###### 

Minimum value of feasibility bound $\alpha_{n + 1}^{\text{min}}$ that leads to incoherent dose-escalation for patient *n* + 1 following *n* patients dosed under the original EWOC approach with fixed feasibility bound, assuming that patient *n* has a DLT

  Patient (*n*)   DLT   Dose   $\alpha_{n + 1}^{\text{min}}$   Patient (*n*)   DLT   Dose   $\alpha_{n + 1}^{\text{min}}$
  --------------- ----- ------ ------------------------------- --------------- ----- ------ -------------------------------
  1               0     140    --                              21              1     279    0.32
  2               0     211    0.50                            22              1     268    0.32
  3               0     243    0.44                            23              0     258    0.32
  4               0     261    0.39                            24              1     260    0.30
  5               0     276    0.39                            25              0     252    0.32
  6               0     290    0.37                            26              1     257    0.32
  7               0     300    0.37                            27              1     246    0.31
  8               0     311    0.34                            28              0     238    0.30
  9               0     319    0.35                            29              0     243    0.32
  10              0     328    0.35                            30              1     245    0.30
  11              1     336    0.34                            31              1     237    0.32
  12              0     320    0.35                            32              1     229    0.30
  13              1     328    0.36                            33              0     223    0.31
  14              1     311    0.33                            34              1     225    0.31
  15              0     297    0.33                            35              0     219    0.30
  16              0     303    0.33                            36              0     222    0.31
  17              1     310    0.34                            37              1     224    0.30
  18              1     297    0.33                            38              1     217    0.31
  19              0     285    0.32                            39              0     212    0.31
  20              1     290    0.32                            40              0     214    0.29

Actual DLT outcomes from simulated trial also given to show progression under EWOC approach with fixed feasibility bound

###### 

Scenarios for simulation study, including number of dose levels and prior distributions

  Scenario   Number of dose levels   *f* (*γ*)                                             *f* (*ρ*~0~)
  ---------- ----------------------- ----------------------------------------------------- -------------------------
  1          286 (every 1 mg/m^2^)   *U* \[*x*~min~ *, x*~max~\]                           *U* \[0*,θ*\]
  2          20 (every 15 mg/m^2^)   *U* \[*x*~min~ *, x*~max~\]                           *U* \[0*,θ*\]
  3          16 (every 19 mg/m^2^)   *U* \[*x*~min~ *, x*~max~\]                           *U* \[0*,θ*\]
  4          6 (every 57 mg/m^2^)    *U* \[*x*~min~ *, x*~max~\]                           *U* \[0*,θ*\]
  5          286 (every 1 mg/m^2^)   *x*~min~ + (*x*~max~ -- *x*~min~) × *Beta* \[3, 7\]   *θ* × *Beta* \[7*,* 3\]
  6          286 (every 1 mg/m^2^)   *x*~min~ + (*x*~max~ -- *x*~min~) × *Beta* \[5, 5\]   *θ* × *Beta* \[5*,* 5\]
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